Emerging technologies in the delivery of erythropoietin for therapeutics

Medicinal Research Reviews

Volumn 31, Issue 2, 2011, Pages 284-309

  Murua, Ainhoa ^a   Orive, Gorka ^a   Hernández, Rosa Ma ^a   Pedraz, José Luis ^a  

^a BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Angiogenesis; Cell microencapsulation; Cell based therapy; Erythropoietin; Neuroprotection; Sustained delivery

Indexed keywords

EPOMAX; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG INFORMATION; DRUG RELEASE; ERYTHROCYTE APLASIA; ERYTHROPOIESIS; GENE THERAPY; HEMATOCRIT; HUMAN; HYPERTENSION; MEDICAL TECHNOLOGY; NONHUMAN; POLYCYTHEMIA; SEIZURE; THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS;

EID: 79551538217     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20184     Document Type: Article

References (221)

1. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007;59:185-205.
2. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
3. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie JJ. Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. Am Soc Nephrol 1999;10:2392-2395.
4. Storring PL, Tiplady RJ, Gaines Das RE, Rafferty B, Mistry YG. Lectin-binding assays for the isoforms of human erythropoietin: Comparison of urinary and four recombinant erythropoietins. J Endocrinol 1996;150:401-412.
5. Wide L, Bengtsson C, Berglund B, Ekblom B. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 1995;27:1569-1576.
6. Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 1990;76:121-127.
7. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-1582.
8. Tilbrook PA, Klinken SP. Erythropoietin and erythropoietin receptor. Growth Factors 1999;17:25-35.
9. Sawada K, Krantz SB, Dai CH, Koury ST, Horn ST, Glick AD, Civin CI. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 1990;142:219-230.
10. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 1992;80:1940-1949.
11. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997;273:R1829-R1844.
12. Lacombe C, Mateux P. Biology of erythropoietin. Haematologica 1998;83:724-732.
13. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33:891-896.
14. Widemann A, Johnson RS. Nonrenal regulation of Epo synthesis. Kidney Int 2009;75:682-688.
15. Lundby C, Robach P, Boushel R, Thomsen JJ, Pasmussen P, Koskolou M, Calbet JAL. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol 2008;105:581-587.
16. Lundby C, Hellsten Y, Jensen MBF, Munch AS, Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol 2008;104:1154-1160.
17. Lundby C, Thomsen JJ, Boushell R, Koskolou M, Warberg J, Calbet JAL, Robach P. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 2007;578:309-314.
18. Schuster SJ, Koury ST, Bohler M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992;81:153-159.
19. Mocini D, Leone T, Tubaroa M, Santinia M, Pencob M. Structure, production and function of erythropoietin: Implications for therapeutical use in cardiovascular disease. Curr Med Chem 2007;14:2278-2287.
20. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77:2497-2503.
21. Eckardt KU, Pugh CW, Meier M, Tan CC, Ratcliffe PJ, Kurtz A. Production of erythropoietin by liver cells in vivo and in vitro. Ann N Y Acad Sci 1994;718:50-63.
22. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-1877.
23. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997;378:609-616.
24. Lee FS. Genetic causes of erythrocytosis and the oxygen-sensing pathway. Blood Rev 2008;22:321-332.
25. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81:2223-2236.
26. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990, 86:681-687.
27. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-659.
28. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor lens. Characterization and affinity cross-linkage. J Biol Chem 1987;262:13985-13990.
29. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol 1998;5:171-176.
30. Handelman GJ, Levin NW. Iron and anemia in human biology: A review of mechanisms. Heart Fail Rev 2008;13:393-404.
31. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:143-156.
32. Pillai A, Mahadik SP. Differential effects of haloperidol and olanzapine on the expression of erythropoietin and its receptor in rat hippocampus and striatum. J Neurochem 2006;98:1411-1422.
33. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-274.
34. Tan CC, Eckardt KU, Ratcliffe PJ. Organ distribution of erythropoietin messenger RNA in normal and uremic rats. Kidney Int 1991;40:69-76.
35. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: Role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002;11:863-871.
36. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD. Origin and fate of erythropoietin in human milk. Pediatr Res 2000;48:660-667.
37. Fandrey J, Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: Measurement by competitive polymerase chain reaction. Blood 1993;81:617-623.
38. Vogt C, Pentz S, Rich IN. A role for the macrophage in normal hemopoiesis: III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp Hematol 1989;17:391-397.
39. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J 1996;10:760-768.
40. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488-19493.
41. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, Mackenzie ET, Petit E. Neurons and astrocytes express Epo mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000;30:271-278.
42. Mengozzi M, Latini R, Salio M, Sfacteria A, Piedimonte G, Gerwien JG, Leist M, Siren AL, Ghezzi P, Chimenti S. Increased erythropoietin production after myocardial infarction in mice. Heart 2006;92:838-839.
43. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031-1033.
44. Buemi M, Caccamo C, Nostro L, Cavallaro E, Floccari F, Grasso G. Brain and cancer: The protective role of erythropoietin. Med Res Rev 2005;25:245-259.
45. Peterson AL, Nutt JG. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008;5:270-280.
46. Brines M, Cerami A. Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-432.
47. Tomczak-Watras W, Strózecki P, Zuchora Z, Szefer J, Manitius J. Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients. Pol Arch Med Wewn 2009;119:45-51.
48. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: A meta-analysis. Clin J Am Soc Nephrol 2009;4:755-762.
49. Okada T, Sawada T, Kubota K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation 2007;84:504-510.
50. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transaction. Exp Neurol 2007;205:48-55.
51. Brettschneider J, Widl K, Schattauer D, Ludolph AC, Tumani H. Cerebrospinal fluid erythropoietin (Epo) in amyotrophic lateral sclerosis. Neurosci Lett 2007;416:257-260.
52. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol 2007;44:212-217.
53. Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: Perplexities and perspectives. Br J Haematol 2009;146:127-141.
54. Patel S, Rowe MJ, Winters SA, Ohls RK. Elevated erythropoietin mRNA and protein concentrations in the developing human eye. Pediatric Res 2008;63:394-397.
55. Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int 2007;99:162-165.
56. King VR, Averill SA, Hewazy D, Priestley JV, Torup L, Michael-Titus AT. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007;26:90-100.
57. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Irkorucu O, Karakaya K, Balbaloglu H, Kertis G, Ankarali H, Comert M. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 2007;13:6172-6182.
58. Hochhauser E, Pappo O, Ribakovsky E, Ravid A, Kurtzwald E, Cheporko Y, Lelchuk S, Ben-Ari Z. Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfusion in an isolated mouse liver model. Apoptosis 2008;13:77-86.
59. Guneli E, Cavdar Z, Islekel H, Sarioglu S, Erbayraktar S, Kiray M, Sokmen S, Yilmaz O, Gokmen N. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med 2007;13:509-517.
60. Fenjves ES, Ochoa MS, Gay-Rabinstein C, Molano RD, Pileggi A, Mendez AJ, Inverardi L, Ricordi C. Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets. Transplantation 2004;77:13-18.
61. Yamazaki T, Kanzaki M, Kamidono S, Fujisawa M. Effect of erythropoietin on leydig cell is associated with the activation of stat5 pathway. Mol Cell Endocrinol 2004;213:193-198.
62. Kao R, Xenocostas A, Rui T, Yu P, Huang W, Rose J, Martin CM. Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit Care 2007;11:R58.
63. Coleman T, Brines M. Science review: Recombinant human erythropoietin in critical illness: A role beyond anemia? Crit Care 2004;8:337-341.
64. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:494-505.
65. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Müller M, Hassouna I, Hannke K, Sperling S, Radyushkin K, El-Kordi A, Schulze L, Ronnenberg A, Wolf F, Brose N, Rhee JS, Zhang W, Ehrenreich H. Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 2008;9:37-52.
66. Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, Imai E, Nonomura N, Takahara S, Okuyama A. Carbamylated erythropoietin improves angiogenesis and protects the kidneys from ischemia-reperfusion injury. Cell Transplant 2008;17:135-141.
67. Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 2000;18:13-17.
68. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006;316:999-1005.
69. Erbayraktar S, de Lanerolle N, de Lotbiniere A, Knisely JP, Erbayraktar Z, Yilmaz O, Cerami A, Coleman TR, Brines M. Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 2006;12:74-80.
70. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
71. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27:552-563.
72. Grasso G, Sfacteria A, Erbayraktar S, Passalacqua M, Meli F, Gokmen N, Yilmaz O, La Torre D, Buemi M, Iacopino DG, Coleman T, Cerami A, Brines M, Tomasello F. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006;4:310-318.
73. Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, Cerami A, Brines M. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 2006;103:5965-5970.
74. Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S, Bigini P, Barbera S, Fumagalli E, Mennini T, Vezzani A, Rizzi M, Coleman T, Cerami A, Brines M, Ghezzi P, Bianchi R. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006;172:27-37.
75. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005;102:2046-2051.
76. Erbayraktar S, Yilmaz O, Gokmen N, Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2003;2:465-470.
77. Banks WA. Delivery of peptides to the brain: Emphasis on therapeutic development. Biopolymers 2008;90:589-594.
78. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Progr Drug Res 2003;61:39-78.
79. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-1388.
80. Juillerat-Jeanneret L, Schmitt F. Chemical modifcation of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail. Med Res Rev 2007;27:574-590.
81. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-651.
82. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 2001;101:271-276.
83. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxiaischemia. Pediatr Res 2005;58:297-301.
84. Aydin A, Genc K, Akhisaroglu M, Yorukoglu K, Gokmen N, Gonullu E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev 2003;25:494-498.
85. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Iacopino DG. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 2007;1182:99-105.
86. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99:9450-9455.
87. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: Effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004;27:113-120.
88. Vitellaro-Zuccarello L, Mazzetti S, Madaschi L, Bosisio P, Fontana E, Gorio A, de Biasi S. Chronic erythropoietin-mediated effects on the expression of astrocyte markers in a rat model of contusive spinal cord injury. Neuroscience 2008;151:452-466.
89. Chang Z-Y, Chiang C-H, Lu D-W, Yeh M-K. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection. Expert Opin Drug Deliv 2008;5:1313-1321.
90. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanorelle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
91. Campana WM, Misasi R, O'Brien JS. Identification of a neurotrophic sequence in erythropoietin. Int J Mol Med 1998;1:235-241.
92. Buemi M, Aloisi C, Cavallaro E, Corica F, Floccari F, Grasso G, Lasco A, Pettinato G, Ruello A, Sturiale A, Frisina N. Recombinant human erythropoietin (rHuEpo): More than just the correction of uremic anemia. J Nephrol 2002;15:97-103.
93. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-11617.
94. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
95. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
96. Karaca M, Odabasoglu F, Kumtepe Y, Albayrak A, Cadirci E, Keles ON. Protective effects of erythropoietin on ischemia/reperfusion injury of rat ovary. Eur J Obstet Gynecol Reprod Biol 2009;144:157-162.
97. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-994.
98. Prunier F, Pottier P, Clairand R, Mercier A, Hajjar RJ, Planchon B, Furber A. Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect. Cardiology 2009;112:129-134.
99. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
100. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018-2027.
101. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007;292:H522-H529.
102. Roncalli JG, Tongers J, Renault M-A, Losordo DW. Endothelial progenitor cells in regenerative medicine and cancer: A decade of research. Trends Biotechnol 2008;26:276-283.
103. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: Ready for prime-time cardioprotection. Trends Pharmacol Sci 2008;29:258-267.
104. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
105. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEpo) increases endothelin-1 release by endothelial cells. Kidney Int 1993;43:1010-1014.
106. Ksiazek A, Zaluska WT, Ksiazek P. Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin Nephrol 2001;56:104-110.
107. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50:1255-1261.
108. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DB. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991;261:E642-E646.
109. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-548.
110. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79-85.
111. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J Biol Chem 2004;279:20655-20662.
112. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J Am Coll Cardiol 2006;48:2161-2171.
113. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 2008;45:567-581.
114. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
115. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
116. Littlewood TJ, Bejetta E, Nortier W. Effects of Epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
117. Goldrick A, Olivotto IA, Alexander CS, Speers CH, Barnett J, Allan SJ, Truong PT. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol 2007;14:227-233.
118. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
119. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999;17:2840-2846.
120. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: Development of a prediction model. Lancet Oncol 2005;6:856-863.
121. Seshadri T, Prince HM, Bell DR, Coughlin PB, James PP, Richardson GE, Chern B, Briggs P, Norman J, Olver IN, Karapetis C, Stewart J. Australian Cancer Anaemia Study Group. The Australian Cancer Anaemia Survey: A snapshot of anaemia in adult patients with cancer. Med J Aust 2005;182:453-457.
122. Barrett-Lee P, Bokemeyer C, Gascón P, Nortier JW, Schneider M, Schrijvers D, Van Belle S. ECAS Advisory Board and Participating Centers Management of cancer-related anemia in patients with breast or gynecologic cancer: New insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-757.
123. Thatcher N, De Campo ES, Bell DR. Epoietin alpha prevents anemia and reduces transfusion requirement in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
124. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-163.
125. O'Shaughnessy J. Effects of Epoetin alfa on cognitive function, mood, asthenia, a quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002;3:S116-S120.
126. Vansteenkiste J, Rossi G, Foote MA. DarbEpoetin alfa: A new approach to the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther 2003;3:501-508.
127. Acs G, Acs P, Beckwith SM, Pittis RL, Clements E, Wong K, Verma G. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565.
128. Mikhail A, Covic A, Goldsmith D. Stimulating erythropoiesis: Future perspectives. Kidney Blood Press Res 2008;31:234-246.
129. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
130. Olthof AW, Sijens PE, Kreeftenberg HG, Kappert P, Irwan R, van der Jagt EJ, Oudkerk M. Correlation between serum ferritin levels and liver iron concentration determined by MR imaging: Impact of hematologic disease and inflammation. Magn Reson Imaging 2007;25:228-231.
131. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, Invernizzi R, Barosi G, Martini A. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemiconset juvenile chronic arthritis. Blood 1996;87:4824-4830.
132. Kendall RG. Erythropoietin. Clin Lab Haematol 2001;23:71-80.
133. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Brit J Haematol 1998;100:79-89.
134. Shermock KM, Horn E, Lipsett PA, Provonost PJ, Dorman T. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005;33:497-503.
135. Laird J. Erythropoietin: Can we afford to use it? Can we afford not to? Transfus Med 2006;16:204-205.
136. Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. Williams hematology. New York: McGraw-Hill Companies; 2006. 1856p.
137. Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents: A guide to selection for anaemia of chronic kidney disease. Drugs 2004;64:499-509.
138. Goto M, Akai K, Murakami A, Haschimoto C, Tsuda E, Ueda M, Kawanishi G, Takahashi N, Ishimoto A, Chiba H, Sasaki R. Production of recombinant human erythropoietin in mammalian cells: Host-cell dependency of the biological activity of the cloned glycoprotein. Biotechnology 1988;6:67-71.
139. Jelkmann W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 2008;141:287-297.
140. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-421.
141. Egrie JC, Browne JK. Br J Cancer 2001;84:3-10.
142. Jelkmann W. Recombinant Epo production-Points the nephrologist should know. Nephrol Dial Transplant 2007;22:2749-2753.
143. Wiecek A, Mikhail A. European regulatory guidelines for biosimilars. Nephrol Dial Transplant 2006;21:v17-v20.
144. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993;10:307-377.
145. Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol 2008;54:529-541.
146. Fabrol EE, Bigey P, Beuzard Y, Scherman D, Payen E. Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment. Gen Vaccines Ther 2008;6:10-15.
147. Topf JM. CERA: Third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-849.
148. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009;16:117-130.
149. Perugini M, Varelias A, Sadlon T, D'Andrea RJ. Hematopoietic growth factor mimetics: From concept to clinic. Cytokine Growth Factor Rev 2009;20:87-94.
150. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM. CNTO 530 functions as a potent Epo mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009;113:4955-4962.
151. Jelkmann W. Erythropoiesis stimulating agents and techniques: A challenge for doping analysts. Curr Med Chem 2009;16:1236-1247.
152. Macdougall IC. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-207.
153. FibroGen Inc. 2009.
154. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T, Yamamoto M. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 2003;17:1742-1744.
155. Debeljak N, Sytkowski AJ. Erythropoietin: New approaches to improved molecular designs and therapeutic alternatives. Curr Pharm Des 2008;14:1302-1310.
156. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005;24:465-475.
157. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215.
158. Lee DE, Oh MS, Chung BS, Park JS, Kim KW. Fusion protein having enhanced in vivo activity of erythropoietin. US7098318; 2006.
159. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101:9763-9768.
160. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M, Rizzuto G, Costa P, Perretta G, Ciliberto G, La Monica N. Gene electro-transfer of an improved erythropoietin plasmid in mice and nonhuman primates. J Gene Med 2005;7:228-236.
161. Hojman P, Gissel H, Gehl J. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 2007;14:950-959.
162. Sebestyén MG, Hegge JO, Noble MA, Lewis DL, Herweijer H, Wolff JA. Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 2007;18:269-285.
163. Richard-Fiardo P, Payen E, Chevre R, Zuber J, Letrou-Bonneval E, Beuzard Y, Pitardi B. Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Hum Gene Ther 2008;19:331-342.
164. Osada S, Ebihara I, Setoguchi Y, Takahashi H, Tomino Y, Koide H. Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999;55:1234-1240.
165. Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N, Savino R. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000;11:859-868.
166. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ, Moullier P. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004;103:3303-3304.
167. Johnston J, Tazelaar J, Rivera VM, Clackson T, Gao GP, Wilson JM. Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. Mol Ther 2003, 7:493-497.
168. Oh TK, Quan GH, Kim HY, Park F, Kim ST. Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol 2006;26:326-334.
169. Venkatesan N, Uchino K, Amagase K, Ito Y, Shibata N, Takada K. Gastro-intestinal patch system for the delivery of erythropoietin. J Control Release 2006;111:19-26.
170. Lejnieks DV, Ramesh N, Lau S, Osborne WR. Stomach implant for long-term erythropoietin expression in rats. Blood 1998;92:888-893.
171. Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, Mei-Zahav C, Mizrachi S, Liberman Y, Iaina A, Kaplan E, Podjarny E, Zeira E, Harati M, Casadevall N, Shani N, Galun E. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005;106:2280-2286.
172. Geng Y, Yuan W, Wu F, Chen J, He M, Jin T. Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation. J Control Release 2008;130:259-265.
173. Kang CE, Poon PC, Tator CH, Shoichet MS. A new paradigm for local and sustained release of therapeutic molecules to the injured spinal cord for neuroprotection and tissue repair. Tissue Eng Part A 2009;15:595-604.
174. Schwenter F, Schneider BL, Pralong WF, Déglon N, Aebischer P. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 2004;15:669-680.
175. Orive G, De Castro M, Ponce S, Hernández RM, Gascón AR, Bosch M, Alberch J, Pedraz JL. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol Ther 2005;12:283-289.
176. Murua A, De Castro M, Orive G, Hernández RM, Pedraz JL. In vitro characterization and in vivo functionality of erythropoietin-secreting cells immobilized in alginate-poly-L-lysine-alginate microcapsules. Biomacromolecules 2007;8:3302-3307.
177. Murua A, Orive G, Hernández RM, Pedraz JL. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. J Control Release 2009;137:174-178.
178. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM, Leiden JM. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996;93:10876-10880.
179. Jiao S, Williams P, Berg RK, Hodgeman BA, Liu L, Repetto G, Wolff JA. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 1992;3:21-33.
180. Vitadello M, Schiaffino WV, Picard A, Scarpa M, Schiaffino S. Gene transfer in regenerating muscle. Hum Gene Ther 1994;5:11-18.
181. Van Deutekon JC, Hoffman EP, Huard J. Muscle maturation: Implications for gene therapy. Mol Med Today 1998;5:214-220.
182. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, Mathiesen I, Cortese R, Ciliberto G, Laufer R, La Monica N, Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999;11:6417-6422.
183. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003;29:371-387.
184. Muramatsu T, Arakawa S, Fukazawa K, Fujiwara Y, Yishida T, Sasaki R, Masuda S, Park HM. In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Int J Mol Med 2001;7:37-42.
185. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867-870.
186. Gehl J, Sorensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, Mir LM. In vivo electroporation of skeletal muscle: Threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999;1428:233-240.
187. Maruyama H, Ataka K, Gejyo F, Higuchi N, Ito Y, Hirahara H, Imazeki I, Hirata M, Ichikawa F, Neichi T, Kikuchi H, Sugawa M, Miyazaki J. Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Ther 2001;8:461-468.
188. Ataka K, Maruyama H, Neichi T, Miyazaki J, Gejko F. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 2003;23:315-323.
189. Rizzuto G, Cappelletti M, Mennuni C, Wiznerowicz M, DeMartis A, Maione D, Ciliberto G, La Monica N, Fattori E. Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000;11:1891-1900.
190. Payen E, Bettan M, Rouyer-Fessard P, Beuzard Y, Scherman D. Improvement of mouse [beta]-thalassemia by electrotransfer of erythropoietin cDNA. Exp Hematol 2001;29:295-300.
191. Samakoglu S, Fattori E, Lamartina S, Toniatti C, Stockholm D, Heard JM, Bohl D. betaMinor-globin messenger RNA accumulation in reticulocytes governs improved erythropoiesis in beta thalassemic mice after erythropoietin complementary DNA electrotransfer in muscles. Blood 2001;97:2213-2220.
192. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
193. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996;93:14070-14075.
194. Zufferey R, Dull T, Mendal RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. Self-inactivating lentivirus vector for safe efficient in vivo gene delivery. J Virol 1998;72:9873-9880.
195. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM. Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1 based lentiviral vectors. Proc Natl Acad Sci USA 1999;96:2988-2993.
196. Seppen J, Barry SC, Harder B, Osborne WRA. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 2001;98:594-596.
197. Schmidt JJ, Rowley J, Kong HJ. Hydrogels used for cell-based drug delivery. J Biomed Mater Res 2008;87A:1113-1122.
198. Dove A. Cell-based therapies go live. Nat Biotechnol 2002;20:339-343.
199. Kong HJ, Mooney DJ. Microenvironmental regulation of biomacromolecular therapies. Nat Rev Drug Discov 2007;6:455-463.
200. Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008;60:124-145.
201. Orive G, Hernández RM, Gascón AR, Calafiore R, Chang TMS, De Vos P, Hortelano G, Hunkeler D, Lacík I, Shapiro AMJ, Pedraz JL. Cell encapsulation: Promise and progress. Nat Med 2003;9:104-107.
202. BlancoBose WE, Schneider BL, Aebischer P. Inducing tolerance to a soluble foreign antigen by encapsulated cell transplants. Mol Ther 2006;13:447-456.
203. Schneider BL, Schwenter F, Pralong WF, Aebischer P. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther 2003;7:506-514.
204. Rinsch C, Peduto G, Schneider BL, Aebischer P. Inducing host acceptance to encapsulated xenogeneic myoblasts. Transplantation 2001;71:345-351.
205. Orive G, Tam SK, Pedraz JL, Hallé JP. Biocompatibility of alginate-poly-L-lysine microcapsules for cell therapy. Biomaterials 2006;27:3691-3700.
206. Thanos CG, Bintz BE, Emerich DF. The stability of alginate-polyornithine microcapsules is profoundly dependent on the site of transplantation. J Biomed Mater Res A 2007;81:1-11.
207. Murua A, Portero A, Orive G, Hernández RM, de Castro M, Pedraz JL. Cell microencapsulation technology: Towards clinical application. J Control Release 2008;132:76-83.
208. Zhang H, Zhu S-J, Wang W, Weil Y-J, Hul S-S. Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function. Gene Ther 2008;15:40-48.
209. Leinfelder U, Brunnenmeier F, Cramer H, Schiller J, Arnold K, Vásquez JA, Zimmermann U. A highly sensitive cell assay for validation of purification regimes of alginates. Biomaterials 2003;24:4161-4172.
210. Juste S, Lessard M, Henley N, Ménard M, Hallé JP. Effect of poly-L-lysine coating on macrophage activation by alginate-based microcapsules: Assessment using a new in vivo method. J Biomed Mater Res A 2005;72:389-398.
211. Orive G, Ponce S, Hernández RM, Gascón AR, Igartua M, Pedraz JL. Biocompatibility of microcapsules for cell immobilization elaborated with different type of alginates. Biomaterials 2002;23:3825-3831.
212. Orive G, Hernández RM, Gascón AR, Igartua M, Pedraz JL. Survival of different cell lines in alginate-agarose microcapsules. Eur J Pharm Sci 2003;18:23-30.
213. Orive G, Carcaboso AM, Hernández RM, Gascón AR, Pedraz JL. Biocompatibility evaluation of different alginates and alginate-based microcapsules. Biomacromolecules 2005;6:927-931.
214. de Groot M, Schuurs TA, Leuvenink HG, van Schilfgaarde R. Macrophage overgrowth affects neighboring nonovergrown encapsulated islets. J Surg Res 2003;115:235-241.
215. Ponce S, Orive G, Hernández RM, Gascón AR, Canals JM, Muñoz MT, Pedraz JL. In vivo evaluation of Epo-secreting cells immobilized in different alginate-PLL microcapsules. J Control Release 2006;116:28-34.
216. Murua A, Orive G, Hernández RM, Pedraz JL. Cryopreservation based on freezing protocols for the long-term storage of microencapsulated myoblasts. Biomaterials 2009;30:3495-3501.
217. Ye X, Rivera VM, Zoltick P, Cerasoli F, Jr, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999;283:88-91.
218. Rendahl KG, Quiroz D, Ladner M, Coyne M, Seltzer J, Manning WC, Escobedo JA. Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. Hum Gene Ther 2002;13:335-342.
219. Nordstrom JL. The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids 2003;68:1085-1094.
220. Wells DJ. Gene doping: The hype and the reality. Br J Pharmacol 2008;154:623-631.
221. Murua A, Orive G, Hernández RM, Pedraz JL. Epo delivery by genetically engineered C2C12 myoblasts immobilized in microcapsules. In: Orive G, Pedraz JL, editors. Therapeutic applications of cell microencapsulation. Austin, TX: Landes Bioscience; 2008.